Peer-influenced content. Sources you trust. No registration required. This is HCN.

The New England Journal of MedicineRucaparib or Physician’s Choice in Metastatic Prostate Cancer

An inhibitor of poly(ADP-ribose) polymerase (PARP), rucaparib, demonstrated high levels of efficacy in patients with metastatic, castration-resistant prostate cancer coupled with a harmful BRCA change in a phase 2 research. To support and add to the findings of the phase 2 trial, data are required.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form